Lundbeckfonden / Lundbeck Foundation company information, Employees & Contact Information

Lundbeck and OpenAI join forces to unlock innovation and boost productivity PharmiWeb.com

Lundbeck Collaborates with Migraine Community to Raise the Bar for Migraine Care Yahoo Finance

The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer - PR Newswire APAC 美通社

Lundbeck raises financial guidance for 2025 TradingView

Advancements in NMDA Receptor-Targeted Antidepressants: From d-Cycloserine Discovery to Preclinical Efficacy of Lu AF90103 | Journal of Medicinal Chemistry ACS Publications

Lundbeck Advances Leadership in Migraine With New Data at the American Headache Society 67th Annual Scientific Meeting Yahoo Finance

WSA welcomes ATHOS KG as a new shareholder and receives new investment to support its long-term development Via Ritzau

Lundbeck successfully places a EUR 500 million Eurobond TradingView

Beyond the pipeline: What it means to commit to innovation in neuro-rare statnews.com

Health Canada Approves Otsuka and Lundbeck's (Pr)ABILIFY ASIMTUFII® (aripiprazole), the First-and-Only, Once-Every-Two-Months, Long-Acting Injectable (LAI) Treatment for Schizophrenia and for Maintenance Monotherapy of Bipolar I Disorder in Adults PR Newswire Canada

Pioneering work in computational and theoretical neuroscience is awarded the world’s largest brain research prize EurekAlert!

Pioneering work in computational and theoretical neuroscience is awarded the world’s largest brain research prize Business Wire

Editorial: Transcription Regulation—Brain Development and Homeostasis—A Finely Tuned and Orchestrated Scenario in Physiology and Pathology Frontiers

Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med Fierce Biotech

Lundbeck Deepens Neuro, Rare Disease Portfolio With $2.6B Longboard Buy BioSpace

Within-Mice Comparison of Microdialysis and Fiber Photometry-Recorded Dopamine Biosensor during Amphetamine Response ACS Publications

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline Business Wire

Continuous Spherical Crystallization of Escitalopram Oxalate without Additives ACS Publications

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD) Business Wire

Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies Wiley Online Library

Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies Taylor & Francis Online

Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older Yahoo Finance

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults Business Wire

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia Business Wire

Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions (1) PharmiWeb.com

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients Wiley Online Library

Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents Business Wire

H. Lundbeck A/S: Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD Finansavisen

Health Canada approves Lundbeck's (Pr)VYEPTI® (eptinezumab)--the first and only intravenous preventive treatment for migraine PR Newswire

Lundbeck's Taj Bhardwaj: Market Access and Mental Health Pharmaceutical Executive

H. Lundbeck A/S: Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy Finansavisen

Lundbeck Acquires Abide Therapeutics for $250M, Gains San Diego Discovery Site BioSpace

Lundbeck to acquire Alder BioPharmaceuticals – a company GlobeNewswire

Lundbeck to acquire Abide Therapeutics, adding a unique GlobeNewswire

Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies The Manila Times

Cara Dignum appointed Managing Director at Lundbeck Women's Agenda

New international Pioneer Centre for medical data research Aarhus BSS

Rexulti Approved by FDA for Major Depressive Disorder and Schizophrenia Fierce Biotech